Advertisement
UK markets close in 7 hours 23 minutes

  • FTSE 100

    8,061.87
    +38.00 (+0.47%)
     

  • FTSE 250

    19,666.27
    +66.88 (+0.34%)
     

  • AIM

    751.78
    +2.60 (+0.35%)
     

  • GBP/EUR

    1.1575
    -0.0013 (-0.11%)
     

  • GBP/USD

    1.2358
    +0.0008 (+0.06%)
     

  • Bitcoin GBP

    53,535.94
    +51.08 (+0.10%)
     

  • CMC Crypto 200

    1,394.50
    -20.26 (-1.43%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    82.48
    +0.58 (+0.71%)
     

  • GOLD FUTURES

    2,324.00
    -22.40 (-0.95%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,824.88
    +313.19 (+1.90%)
     

  • DAX

    17,987.60
    +126.80 (+0.71%)
     

  • CAC 40

    8,056.93
    +16.57 (+0.21%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

COMPASS Pathways plc to participate in Cowen's 41st Annual Health Care Conference

Compass Pathways
·1-min read

New York, NY, Feb. 26, 2021 (GLOBE NEWSWIRE) -- George Goldsmith, Chairman & CEO, to participate in Neuropsych Panel discussion

London, UK – 26 February 2021

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in Cowen's 41st Annual Health Care Conference. George Goldsmith, Chairman, CEO and Co‑founder, will participate in the Neuropsych Panel discussion at 1:20pm ET on 1 March.

-Ends-

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com

Contacts:


Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401-290-7324